Key Highlights
- Hims & Hers (HIMS) shares declined approximately 6.4% during Tuesday’s premarket session following Q4 results and disappointing forward guidance
- Fourth-quarter revenue reached $617.8M, coming in slightly below the anticipated ~$619M consensus from Wall Street analysts, while EPS of $0.08 exceeded projections
- First-quarter 2026 revenue outlook of $600M–$625M significantly underperformed analyst projections of approximately $653M
- Federal regulators escalated enforcement actions, with the FDA forwarding Hims to the Justice Department regarding possible Food, Drug, and Cosmetic Act violations
- Year-to-date performance shows HIMS shares declining over 52% in 2026, facing headwinds from litigation by Novo Nordisk and heightened regulatory oversight
Hims & Hers Health released its fourth-quarter financial results following Monday’s market close, delivering outcomes that left investors concerned about future performance.
$HIMS (Hims & Hers Health) #earnings are out: pic.twitter.com/MnluzGJYXz
— The Earnings Correspondent (@earnings_guy) February 23, 2026
The company reported Q4 earnings per share of $0.08, surpassing analyst consensus estimates that ranged from $0.04 to $0.05. Revenue figures totaled $617.8 million, falling marginally below Wall Street’s anticipated range of $618.7–$619.2 million.
Shares experienced a decline of approximately 6.4% during Tuesday’s premarket session, trading around $14.48.
Hims & Hers Health, Inc., HIMS
The primary concern for investors centered on forward-looking projections rather than the modest Q4 shortfall. Management provided Q1 2026 revenue guidance ranging from $600 million to $625 million, substantially below analyst expectations near $653 million. This meaningful discrepancy captured market attention immediately.
The company’s adjusted EBITDA forecast for Q1 stands at $35 million to $55 million, which Citi Research analyst Daniel Grosslight characterized as “particularly weak,” noting the projection implies aggressive growth acceleration throughout subsequent quarters linked to upcoming product introductions.
Full-year 2026 guidance calls for revenue between $2.7 billion and $2.9 billion, aligning closely with analyst consensus of $2.74–$2.75 billion, alongside adjusted EBITDA projections of $300 million to $375 million.
Truist Securities analysts observed the guidance assumes considerable sequential momentum building throughout 2026, suggesting after-hours trading activity reflected “limited visibility beyond Q1.”
Annual projections exclude any potential revenue contribution from the recently announced Eucalyptus acquisition, the Australian telehealth company Hims agreed to purchase last week with an expected mid-2026 closing timeline.
The company’s subscriber base expanded 13% year-over-year, reaching 2.5 million at year-end. CEO Andrew Dudum emphasized the rollout of Labs, a diagnostic and health monitoring platform, describing it as integral to the company’s vision of becoming a “global leader in consumer health.”
Intensifying Regulatory and Legal Challenges
Financial performance represented only one source of pressure on shares. HIMS has encountered substantial legal and regulatory challenges throughout 2026.
Earlier this month, Novo Nordisk initiated patent infringement litigation against Hims, challenging the company’s compounded formulations of Wegovy. Hims issued public statements defending its position while announcing it would discontinue sales of a $49 tablet containing semaglutide, the active pharmaceutical ingredient in Novo’s weight-loss medication.
The company continues offering compounded GLP-1 injection products through its online platform, typically priced considerably below brand-name alternatives from Novo and Eli Lilly.
The FDA subsequently released a statement committing to “take action against non-FDA-approved GLP-1 drugs,” specifically identifying compounding pharmacies such as Hims as enforcement priorities. FDA general counsel Mike Stuart announced the agency was forwarding Hims to the Justice Department concerning potential violations of the Food, Drug, and Cosmetic Act.
Short Positioning and Market Performance
Short interest levels in HIMS reached their highest point in at least twelve months during January, according to Reuters data.
Shares have declined more than 52% year-to-date in 2026 and over 69% across the trailing twelve-month period.
Grosslight anticipates investors will concentrate on management commentary surrounding the company’s GLP-1 product line, which he estimates contributes approximately one-third of overall revenue.
The company’s first-quarter 2026 outlook and its approach to compounded GLP-1 products represent the primary areas of investor attention heading into subsequent quarters.
